Published in Antimicrob Agents Chemother on May 30, 2017
The 7H11 medium for the cultivation of mycobacteria. Am Rev Respir Dis (1968) 4.23
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2003) 3.76
Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis (2011) 2.50
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med (2015) 2.48
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
What is the 'right' dose of rifampin? Int J Tuberc Lung Dis (2003) 1.53
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clin Infect Dis (2011) 1.52
Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs (2014) 1.34
Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother (2007) 1.34
Two three-month treatment regimens for pulmonary tuberculosis. Bull Int Union Tuberc (1976) 1.19
Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother (2009) 1.08
Binding of rifampicin by human plasma proteins. Eur J Clin Pharmacol (1974) 1.01
Optimizing the clinical pharmacology of tuberculosis medications. Clin Pharmacol Ther (2015) 0.87
A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis. Int J Tuberc Lung Dis (2016) 0.83
The pharmacokinetics of a single oral or rectal dose of concurrently administered isoniazid, rifampin, pyrazinamide, and ethambutol in Asian elephants (Elephas maximus). J Vet Pharmacol Ther (2014) 0.79
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis (2016) 0.79
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis (2016) 0.79
A Step toward an Optimized Rifampin Dose Completed. Am J Respir Crit Care Med (2015) 0.78
Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis". Antimicrob Agents Chemother (2017) 0.75